Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a ...

NervGen Pharma (TSE:NGEN) has released an update. NervGen Pharma, a clinical-stage biotech company, is set to present at the Stifel 2024 ...

The race moves to the November general election for the four-year term of District 5 Cape Coral City Council representative, featuring Joseph Kilraine and Charlie Pease who made it through the ...

The stock rose after the company reported its second quarter earnings for the financial year 2024-25 (Q2FY25). GSK Pharma reported a 16 per cent year-on-year increase in its consolidated net profit, ...

FREIBURG, GERMANY / ACCESSWIRE / October 29, 2024 / Today, Dr. Falk Pharma GmbH announces the successful acquisition of Kynos Therapeutics Ltd., a clinical stage biopharmaceutical company focusing on ...

API’s external sales increased 7% year on year to ₹534 Crore in the second quarter. Sun Pharma has bolstered its speciality pipeline with a partnership with Philogen to commercialise late ...

Sun Pharma has seen a positive price breakout, currently trading above its third resistance level (R3) with a price of Rs 1914.45, just above R3 at Rs 1913.03. Sun Pharma is currently priced at Rs ...

German drugmaker Dr Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company focusing on the development of novel KMO inhibitors ...

The market is seeing strong growth primarily driven by a growing population. (Image Credits: Pixabay) Emcure Pharmaceuticals Limited on Monday announced that it is set to cater to a growing ...

Strides Pharma reported Q2 FY25 net profit of ₹93 Crore, marking a recovery from a ₹131 Crore loss in the same quarter last year. Revenue for Q2 FY25 reached ₹1,201 Crore, reflecting a 20.2% ...

Q2 Results 2024: Majors like Bharti Airtel, Sun Pharma, Adani Power, Indian Oil, Ambuja Cements, Punjab National Bank, Federal Bank, Indraprastha Gas, Pfizer, and others are releasing their Q2 ...